Friday, January 13, 2017 9:57:48 AM
MDMN management is doing what they believe is best for the company. If this does not appeal shareholders and they believe that it will only cause the company to lose money, thereby hurting current shareholders, then they are free to sell and move on. In fact, I would encourage them to do so. If the financial risk associated with BOD actions is greater than the potential reward, then clearly, holding shares of this company is not advisable for those who have engaged in this calculus. At that point, the sound financial decision would be to sell and put the capital into companies who are making better choices.
There may be times when we are powerless to prevent injustice, but there must never be a time when we fail to protest.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM